Latest news

View all

MedTech Business – February 3, 2026

ADDvise has applied for delisting from Nasdaq First North

On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.

Acquisition – February 3, 2026

Nanologica acquires Nordic CDMO

Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.

Biotech Business – February 2, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand

Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Science News – January 30, 2026

AI: Fewer missed cancer cases in breast cancer screening

The final results from Lund University’s MASAI trial are now available.

Global report – January 30, 2026

AstraZeneca enhances its weight management portfolio

AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.

Opinion & debate

Clinical Trials

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Clinical Trials – January 27, 2026

Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study

The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).

Clinical Trials – January 27, 2026

DexTech Medical’s myeloma study, completed at the end of February

The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Clinical Trials – January 8, 2026

Herantis Pharma reports encouraging data from Phase 1b trial

Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Nobel Prize Laureate – December 20, 2018

Frances H. Arnold: Better than Nature herself

Read Chris Tachibana’s exclusive interview with Frances H. Arnold, a Nobel Laureate in Chemistry 2018, and learn more about her bold approaches to optimizing enzymes for society’s benefit.

Sponsored content

Detecting heavy metal with confidence – the Shimadzu ALTRACE

The ALTRACE is the new flagship model of Shimadzu’s energy dispersive X-ray fluorescence spectrometers.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • The Nobel Prize: Exclusive interviews with Mary Brunkow, Fred Ramsdell, Shimon Sakaguchi, and Omar Yaghi. Deepen your knowledge on Tregs, MOFs, and quantum technology.
  • Hot topics: What are the effects of climate change on health and how far have we come within organ and tissue repair?
  • Business: Learn more about a career as Chief Financial Officer and the next generation of entrepreneurs in Iceland. Exclusive interview with Leif Johansson, former Chairman of AstraZeneca.
Subscribe now

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.